Evidence map›Paper›PMID 32021428›Full record

ArticleCancer management and research2020

Validity of serum amyloid A and HMGB1 as biomarkers for early diagnosis of gastric cancer.

Ali A Ghweil, Heba A Osman, Mohammed H Hassan, Abeer Mm Sabry, Reem E Mahdy, Ahmed Rh Ahmed, Ahmed Okasha, Ashraf Khodeary, Hesham H Ameen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Ali A GhweilTropical Medicine and Gastroenterology Department, Faculty of Medicine, South Valley University, Qena, Egypt.
Heba A OsmanTropical Medicine and Gastroenterology Department, Faculty of Medicine, South Valley University, Qena, Egypt.
Mohammed H HassanDepartment of Medical Biochemistry, Faculty of Medicine, South Valley University, Qena, Egypt.
Abeer Mm SabryInternal Medicine and Gastroenterology Department, Faculty of Medicine, Helwan University, Helwan, Egypt.
Reem E MahdyInternal Medicine Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
Ahmed Rh AhmedPathology Department, Faculty of Medicine, Sohag University, Sohag, Egypt.
Ahmed OkashaRadiology Department, Faculty of Medicine, South Valley University, Qena, Egypt.
Ashraf KhodearyClinical Pathology Department, Faculty of Medicine, Sohag University, Sohag, Egypt.
Hesham H AmeenClinical Pathology Department, Faculty of Medicine, Al-Azhar University (Assiut Branch), Assiut, Egypt.
South Valley University · EGSohag University · EGAl-Azhar University · EGAssiut University · EGHelwan University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimGastric carcinomais a frequent neoplasm with poor outcome, and its early detection would improve prognosis. This study was designed to evaluate the possible use of new biomarkers, namely SAA and HMGB1, for early diagnosis of gastric cancer.

methodsA total of 100 patients presenting with gastric symptoms were included. All patients underwent upper endoscopic evaluation, histopathological diagnosis and serum CEA, SAA, and HMGB1 measurements.

resultsPatients were classed endoscopically with neoplastic, inflammatory, and normal-appearing gastric mucosa: 50, 25, and 25 patients, respectively. Histologically, half the patients had chronic gastritis and the remaining cases gastric carcinoma of diffuse (n=28) or intestinal (n=22) type. SAA at cutoff of 18.5 mg/L had the best validity to differentiate gastritis from gastric carcinoma, with AUC, sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) of 0.99, 98%, 100%, 100%, and 98%, respectively, followed by HMGB1 at cutoff of 14.5 pg/μL, with AUC, sensitivity, specificity, PPV, and NPV of 0.91, 70%, 96%, 94.6%, and 76.2%, respectively. Sensitivity, specificity, PPV, and NPV of serum CEA at cutoff of 2.9 ng/mL to differentiate gastritis from gastric carcinoma were 42%, 72%, 60%, and 55.4%, respectively, with AUC of 0.53. Nonetheless, higher serum levels of both SAA and HMGB1 reflected higher tumor grade (

conclusionSerum levels of both SAA and HMGB1 could be of great value for early diagnosis of gastric carcinoma, comparable to the diagnostic role of serum CEA, which is not valid for early diagnosis of gastric cancer.

Indexed as

CEAearly detectiongastric carcinomaHMGB1SAA

Identifiers

PMID32021428
PMCPMC6958557
OpenAlexW2999051509

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.